display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
multiple myeloma - 2nd line (L2)
ovarian cancer (OC)
target therapy
multikinase inhibitor
nintedanib LUME-Ovar 1 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons